Description
Pivotal role of PU.1 and Spi-B in B cell acute lymphoblastic leukemia and lymphoma
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02015-07-01$690,720
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2015-07-01(start date) | $690,720 | — | Pivotal role of PU.1 and Spi-B in B cell acute lymphoblastic leukemia and lymphoma |
Related records · 2
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2025-2026-Q3-00350 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $1,071,000 | FY2026 |
| 236-2020-2021-Q1-00467 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $948,864 | FY2021 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2015-2016-Q2-00799 · retrieved 2026-11-14.